Akero Therapeutics AKRO 深 滬
等待開盤 09-24 09:30:00 美东时间
47.84
+1.430
+3.08%
華盛通- 最 高47.99
- 今 開46.10
- 成交量 90.11万股
- 最 低 46.10
- 昨 收 46.41
- 總市值 38.27亿
- 52周最高 58.40
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 21.34
- 委 比 -23.42%
- 總股本 7998.90万
- 歷史最高 58.40
- 量 比 0.51
- 振 幅 4.07%
- 歷史最低 7.52
- 每 手 1
- 風險率 9.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Roche deal to buy 89bio boosts MASH space
Shares of companies focused on developing drugs for a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Thursday after Roche (OTCQX:RHHBY) (OTCQX:RHHBF) a...
09-18 22:41
HC Wainwright & Co. Assumes Akero Therapeutics at Buy, Announces Price Target of $72
HC Wainwright & Co. analyst Andrew S. Fein assumes Akero Therapeutics (NASDAQ:AKRO) with a Buy rating and announces Price Target of $72.
09-04 19:14
Akero Therapeutics’ Phase 3 NASH Study: A Potential Game-Changer?
Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical stud...
08-20 00:04
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
Results from Akero Therapeutics' Phase 2b HARMONY trial, published in *The Lancet*, demonstrate that efruxifermin (EFX) significantly reduced liver fibrosis and resolved steatohepatitis in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH). At 96 weeks, 49% of participants on 50mg EFX achieved fibrosis improvement without worsening of MASH, compared to 19% on placebo. Additionally, EFX improved liver injury marker...
08-14 22:30
Akero Therapeutics Q2 EPS $(0.86) Beats $(0.93) Estimate
Akero Therapeutics (NASDAQ:AKRO) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(0.93) by 7.53 percent. This is a 6.17 percent decrease over losses of $(0.81) per share from
08-08 19:18
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Akero Therapeutics reported second quarter 2025 financial results, with $1.086 billion in cash and marketable securities, and highlighted key advancements for EFX, its lead candidate for MASH. Phase 2b SYMMETRY study data, published in the New England Journal of Medicine, demonstrated statistically significant reversal of compensated cirrhosis (F4) in patients with MASH. Additional findings at EASL 2025 showed EFX's potential to benefit high-risk...
08-08 11:15
TD Cowen Initiates Coverage On Akero Therapeutics with Buy Rating, Announces Price Target of $76
TD Cowen analyst Ritu Baral initiates coverage on Akero Therapeutics (NASDAQ:AKRO) with a Buy rating and announces Price Target of $76.
08-04 19:38
恒申安科罗年产10万吨改性塑料项目动工
近日，恒申安科罗年产10万吨改性工程材料项目正式动工建设，一期产能为5万吨。据悉，该项目总投资10亿元，占地面积110亩，总建筑面积约15万平方米。企业规划建设...
07-22 18:12
Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH/MASH Treatment
Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical stud...
06-27 00:23
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
Akero Therapeutics announced that its management will present at the Jefferies Global Healthcare Conference on June 4, 2025. The presentation will be webcast live and archived on the company's website. Akero develops treatments for serious metabolic diseases like metabolic dysfunction-associated steatohepatitis (MASH). Its lead candidate, efruxifermin (EFX), is in Phase 3 trials. The company is based in South San Francisco.
05-28 11:00
